Literature DB >> 26887776

Genetic differences between paediatric and adult Burkitt lymphomas.

Violaine Havelange1, Xavier Pepermans2, Geneviève Ameye2, Ivan Théate3, Evelyne Callet-Bauchu4, Carole Barin5, Dominique Penther6, Eric Lippert7, Lucienne Michaux8, Francine Mugneret9, Nicole Dastugue10, Martine Raphaël11, Miikka Vikkula12, Hélène A Poirel1,12.   

Abstract

Dysregulation of MYC is the genetic hallmark of Burkitt lymphoma (BL) but it is encountered in other aggressive mature B-cell lymphomas. MYC dysregulation needs other cooperating events for BL development. We aimed to characterize these events and assess the differences between adult and paediatric BLs that may explain the different outcomes in these two populations. We analysed patterns of genetic aberrations in a series of 24 BLs: 11 adults and 13 children. We looked for genomic imbalances (copy number variations), copy-neutral loss of heterozygosity (CN-LOH) and mutations in TP53, CDKN2A, ID3 (exon 1), TCF3 (exon17) and CCND3 (exon 6). Young patients displayed more frequent 13q31.3q32.1 amplification, 7q32q36 gain and 5q23.3 CN-LOH, while 17p13 and 18q21.3 CN-LOH were only detected in adult BLs. ID3 mutations were present in all adult samples, but only in 42% of childhood cases. CCND3 and ID3 double-hit mutations, as well as 18q21 CN-LOH, seemed to be associated with poorer outcome. For the first time, we report different genetic anomalies between adult and paediatric BLs, suggesting age-related heterogeneity in Burkitt lymphomagenesis. This may explain the poorer prognosis of adult BLs. Additional studies are needed to confirm these results in the setting of clinical trials.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Burkitt lymphoma; CCND3; ID3; SNP-array; childhood

Mesh:

Substances:

Year:  2016        PMID: 26887776     DOI: 10.1111/bjh.13925

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

Review 1.  Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.

Authors:  Adam S Zayac; Adam J Olszewski
Journal:  Leuk Lymphoma       Date:  2020-04-07

2.  Risk factors for Burkitt lymphoma: a nested case-control study in the UK Clinical Practice Research Datalink.

Authors:  Parisa Karimi; Brenda M Birmann; Lesley A Anderson; Charlene M McShane; Shahinaz M Gadalla; Joshua N Sampson; Sam M Mbulaiteye
Journal:  Br J Haematol       Date:  2018-04-20       Impact factor: 6.998

3.  The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.

Authors:  Katrin S Hüttl; Annette M Staiger; Julia Richter; M Michaela Ott; Sabrina Kalmbach; Wolfram Klapper; Anne-Sophie Biesdorf; Lorenz Trümper; Andreas Rosenwald; Marita Ziepert; Heike Horn; German Ott
Journal:  Virchows Arch       Date:  2021-03-02       Impact factor: 4.064

4.  Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.

Authors:  Birgit Burkhardt; Ulf Michgehl; Jonas Rohde; Tabea Erdmann; Philipp Berning; Katrin Reutter; Marius Rohde; Arndt Borkhardt; Thomas Burmeister; Sandeep Dave; Alexandar Tzankov; Martin Dugas; Sarah Sandmann; Falko Fend; Jasmin Finger; Stephanie Mueller; Nicola Gökbuget; Torsten Haferlach; Wolfgang Kern; Wolfgang Hartmann; Wolfram Klapper; Ilske Oschlies; Julia Richter; Udo Kontny; Mathias Lutz; Britta Maecker-Kolhoff; German Ott; Andreas Rosenwald; Reiner Siebert; Arend von Stackelberg; Brigitte Strahm; Wilhelm Woessmann; Martin Zimmermann; Myroslav Zapukhlyak; Michael Grau; Georg Lenz
Journal:  Nat Commun       Date:  2022-07-06       Impact factor: 17.694

5.  Age-related heterogeneity of Burkitt lymphoma.

Authors:  Sam M Mbulaiteye; William F Anderson
Journal:  Br J Haematol       Date:  2016-07-29       Impact factor: 6.998

Review 6.  Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells.

Authors:  Sumedha Roy; Yuan Zhuang
Journal:  Front Med       Date:  2018-07-24       Impact factor: 4.592

Review 7.  Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective.

Authors:  Kieron Dunleavy; Thomas G Gross
Journal:  Blood       Date:  2018-06-12       Impact factor: 22.113

8.  Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.

Authors:  Marius Rohde; Bettina R Bonn; Martin Zimmermann; Jonas Lange; Anja Möricke; Wolfram Klapper; Ilske Oschlies; Monika Szczepanowski; Inga Nagel; Martin Schrappe; Markus Loeffler; Reiner Siebert; Alfred Reiter; Birgit Burkhardt
Journal:  Haematologica       Date:  2017-02-16       Impact factor: 9.941

Review 9.  Burkitt lymphoma in adolescents and young adults: management challenges.

Authors:  Massimo Dozzo; Francesca Carobolante; Pietro Maria Donisi; Annamaria Scattolin; Elena Maino; Rosaria Sancetta; Piera Viero; Renato Bassan
Journal:  Adolesc Health Med Ther       Date:  2016-12-23

10.  Case Reports in Oncological Medicine Myoepithelioma: A New Rearrangement Involving the LPP Locus in a Case of Multiple Bone and Soft Tissue Lesions.

Authors:  Hélène A Poirel; Christine Galant; Géraldine Pairet; Gaëlle Tilman; Rafaël Sciot; Thomas Schubert; Vasiliki Perlepe
Journal:  Case Rep Oncol Med       Date:  2018-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.